IR type tumours were also predicted to be responsive to tumour immunotherapy, as indicated by tumour immune dysfunction and exclusion (TIDE) scores (Fig. 3d).21 These results collectively indicate IR type as highly immunogenic and responsive to anti-PD-1/PD-L1 blockade. Here, PDCD1 is linked to neoplasm.